Innovating Nature, Elevating Health
Dexa Laboratories of Biomolecular Sciences (DLBS) is a research-driven innovation center focused on the discovery, development, and production of pharmaceuticals, biopharmaceuticals, and nutraceuticals. Established in 2005, DLBS is the scientific backbone behind Dexa Group’s modern herbal medicines, translating Indonesia’s rich biodiversity into bioactive, evidence-based therapies through advanced molecular and clinical research.
DLBS pioneers Integrated Modern Natural Medicine—Indonesia’s first modern natural medicine platform—developed using contemporary pharmaceutical technology to reduce reliance on imported raw materials. To date, DLBS has successfully launched 25 products across 7 therapeutic classes, with innovations exported to Singapore, Malaysia, Cambodia, Vietnam, the Philippines, Mongolia, and Nigeria, strengthening Indonesia’s presence in regional and global healthcare markets. DLBS products have been registered in several countries, demonstrating our commitment to meeting global standards and expanding our products internationally.
Operating to the highest international standards, DLBS holds ISO 22000, AAALAC, HALAL, and GMP certifications and collaborates with leading research institutions in the United States, Singapore, and Indonesia. Sustainability is embedded across its innovation pipeline through Green Pharmacy principles, ensuring responsible sourcing, environmentally sound processes, and long-term value creation—advancing healthcare where science, nature, and integrity converge.
For more information please visit our website.
